Cost-effectiveness of first generation nanotherapy: Comparing gemcitabine and PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer in Flanders
examine the costs and cost-effectiveness of chemotherapy (gemcitabine) and a first generation nanotherapy (PEGylated liposomal doxorubicin) to treat ovarian cancer in a Flemish context. The base case used data ... Monte…

